Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Four analysts have recently evaluated Arcus Biosciences (NYSE:RCUS), providing a range of ratings from bullish to bearish. The average 12-month price target has decreased by 9.27% to $34.25. Analysts from Wedbush, Barclays, Truist Securities, and Citigroup have adjusted their ratings and price targets, reflecting their views on the company's market position and financial health.
August 09, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcus Biosciences (NYSE:RCUS) has received mixed ratings from analysts, with a decrease in the average 12-month price target by 9.27% to $34.25. Analysts from Wedbush, Barclays, Truist Securities, and Citigroup have adjusted their ratings and price targets, reflecting their views on the company's market position and financial health.
The mixed ratings and the decrease in the average price target suggest a neutral short-term impact on the stock price. While some analysts have lowered their price targets, others have maintained or raised theirs, indicating diverse opinions on the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100